Intravitreal ranibizumab therapy for symptomatic retinal arterial macroaneurysm

Poster Details

First Author: M.Kaya TURKEY

Co Author(s):    N. Kocak   T. Ozturk   Z. Ayhan   S. Kaynak                    

Abstract Details


To evaluate the anatomic and functional results of intravitreal ranibizumab injection for treatment of symptomatic retinal arterial macroaneurysm (RAM).


Dokuz Eylul University School of Medicine, Izmir, Turkey.


Retrospective interventional case series. A series of seven patients (seven eyes) who had been diagnosed with symptomatic RAM were assessed by comprehensive ophthalmologic examination, fluorescein angiography (FA), and spectral domain optical coherence tomography (SD-OCT). All patients were treated by intravitreal ranibizumab injection within two week of diagnosis and retreated upon evidence of persistent serous detachment or haemorrhage involving the macula on SD-OCT. Anatomical recovery was examined by FA, and OCT. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated using the Snellen chart and optical coherence tomography, respectively, at baseline; at 1, 2, 3, and 6 months; and at the final visit.


The mean follow-up period for all subjects was 14.64 ± 5.2 months. The mean number of injections for the RAM was 1.57 ± 0.64. The mean logarithm of the minimal angle of resolution (LogMAR) of BCVA improved from 0. 96 ± 0.56 to 0.14± 0.12 (p = 0.012) and mean CMT decreased from 456.4 ± 145.6 μm to 216.8 ± 32.4 μm (P = 0.024). No complications were observed with intravitreal ranibizumab injection.


Intravitreal ranibizumab is an effective therapy for symptomatic RAM, quickly improving BCVA and CMT. Intravitreal ranibizumab injection likely hastens resolution of macular edema and haemorrhage secondary to RAM.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy